Tri Locum Partners LP Invests $5.04 Million in Ascendis Pharma A/S $ASND

Key Points

• Tri Locum Partners LP has purchased 32,325 shares of Ascendis Pharma A/S, valued at approximately $5.0 million, making it the firm's 15th largest holding.
• Ascendis Pharma reported a quarterly loss of ($0.93) earnings per share, which surpassed analysts' expectations of ($1.42), alongside revenue of $216.28 million.
• Fifteen investment analysts rated Ascendis Pharma shares as a "buy," with the majority issuing price targets ranging from $224.00 to $290.00.

Tri Locum Partners LP acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 32,325 shares of the biotechnology company's stock, valued at approximately $5,038,000. Ascendis Pharma A/S makes up approximately 2.6% of Tri Locum Partners LP's holdings, making the stock its 15th largest position. Tri Locum Partners LP owned about 0.05% of Ascendis Pharma A/S as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. RA Capital Management L.P. lifted its holdings in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after purchasing an additional 402,316 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock worth $475,970,000 after buying an additional 328,278 shares during the period. Vestal Point Capital LP lifted its stake in Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after buying an additional 270,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares in the last quarter. Finally, Soleus Capital Management L.P. acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $19,824,000.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ASND. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price objective on the stock. Citigroup reissued a "buy" rating and issued a $290.00 price target (up previously from $243.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price target on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Bank of America increased their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Buy" and a consensus target price of $244.36.

Ascendis Pharma A/S Stock Up 4.3%

Shares of NASDAQ ASND traded up $8.27 during trading hours on Tuesday, hitting $202.54. The company had a trading volume of 236,209 shares, compared to its average volume of 489,637. The stock has a market capitalization of $12.40 billion, a P/E ratio of -39.28 and a beta of 0.39. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $203.00. The firm's 50 day moving average is $180.56 and its 200-day moving average is $166.70.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.